Search
In honor of his extraordinary contributions to improving the diagnosis and treatment of childhood cancer, Richard O’Reilly, Chairman of the Department of Pediatrics and Director of the Bone Marrow Transplantation Program at MSK, will receive the first Society of Memorial Sloan Kettering Prize.
MSK researchers shared their latest research developments at the 2021 meeting of the American Association for Cancer Research.
The Prospective Registry Of Multi-Plex Testing (PROMPT) - a new online, volunteer registry for individuals who have been tested for inherited mutations in cancer-causing genes - will provide data vital to improving our understanding of newly discovered, cancer-associated genes and allow current and future generations to better interpret and benefit from knowledge of their genomes.
Learn how MSK is joining forces with the City of New York to expand access to the COVID-19 vaccine.
Memorial Sloan Kettering (MSK) has reached a major milestone in bringing personalized treatments to more cancer patients. Michael Berger, PhD, Ahmet Zehir, PhD, and colleagues have reported an in-depth analysis of the first 10,336 patients whose tumors were submitted for clinical genomic sequencing by MSK-IMPACT™, a powerful diagnostic test developed at MSK to provide detailed genetic information about a patient’s cancer.
Chemotherapy after immune checkpoint inhibitors (ICIs) may improve survival rates in patients with heavily pretreated, recurrent ovarian cancer.
Molecular biologist Christine Mayr, MD, PhD, of Memorial Sloan Kettering’s (MSK) Sloan Kettering Institute (SKI) is one of 12 2016 recipients of the prestigious National Institutes of Health (NIH) Director’s Pioneer Award. Established in 2004, the annual award recognizes and supports individual scientists of exceptional creativity who propose pioneering and highly innovative approaches with the potential to produce an unusually high impact on biomedical or behavioral research.
A member of the Sloan Kettering Institute's Immunology Program and a Howard Hughes Medical Institute investigator, Alexander Rudensky is fascinated by how a specific type of white blood cells called regulatory T cells regulates our immune system.
New MSK research finds a potential target against neuroendocrine transformation in lung and prostate cancers; discovers new clues about why donor T cells attack certain tissues in graft-versus-host disease; sheds light on why T cells let go of their prey; and uses CRISPR interference and dynamic cell-state transitions to discover enhancers that affect early human development.
A summer program offers college students from underrepresented communities a chance to get valuable research experience.